About seven years since its inception, Vectura Ltd. dipped its feet into public waters on Friday, conducting an initial public offering on London's Alternative Investment Market to raise £20 million (US$36.4 million). (BioWorld Today)
Just as researchers geared up to start a second pivotal trial of iseganan in ventilator-associated pneumonia (VAP), the floor fell from beneath IntraBiotics Pharmaceuticals Inc. Wednesday. (BioWorld Today)
In a deal potentially worth $384 million for Vertex Pharmaceuticals Inc., the company entered a global collaboration with Merck & Co. Inc. to develop and commercialize the former's lead aurora kinase inhibitor, VX-680. (BioWorld Today)
